Syros Pharmaceuticals, Inc. - common stock (SYRS): Price and Financial Metrics

Syros Pharmaceuticals, Inc. - common stock (SYRS): $4.54

0.18 (-3.81%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

SYRS Price/Volume Stats

Current price $4.54 52-week high $8.17
Prev. close $4.72 52-week low $2.09
Day low $4.40 Volume 262,900
Day high $4.72 Avg. volume 217,874
50-day MA $6.27 Dividend yield N/A
200-day MA $4.72 Market Cap 121.35M

SYRS Stock Price Chart Interactive Chart >


Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio


Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.


SYRS Latest News Stream


Event/Time News Detail
Loading, please wait...

SYRS Latest Social Stream


Loading social stream, please wait...

View Full SYRS Social Stream

Latest SYRS News From Around the Web

Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., December 19, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,242,588 shares of its common stock at an offering price of $4.419 p

Yahoo | December 19, 2023

individual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last week

Key Insights Syros Pharmaceuticals' significant individual investors ownership suggests that the key decisions are...

Yahoo | December 13, 2023

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Yahoo | December 7, 2023

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

CAMBRIDGE, Mass., December 06, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia

Yahoo | December 6, 2023

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside.

Josh Enomoto on InvestorPlace | December 3, 2023

Read More 'SYRS' Stories Here

SYRS Price Returns

1-mo -27.59%
3-mo -33.82%
6-mo 107.31%
1-year 70.04%
3-year -92.86%
5-year -93.35%
YTD -41.72%
2023 116.99%
2022 -88.99%
2021 -69.95%
2020 57.02%
2019 24.06%

Continue Researching SYRS

Want to see what other sources are saying about Syros Pharmaceuticals Inc's financials and stock price? Try the links below:

Syros Pharmaceuticals Inc (SYRS) Stock Price | Nasdaq
Syros Pharmaceuticals Inc (SYRS) Stock Quote, History and News - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!